The US Food and Drug Administration has become more conservative in allowing evidence from non-inferiority clinical trials when considering approval of new drugs, the Government Accountability Office has found1.
Non-inferiority trials are conducted to determine whether a new treatment is no worse than a reference treatment...
Please login to read the full article.
